These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 26045064)

  • 1. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
    BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.
    Yılmaz I; Ozkok A; Kostek O; Kolukısa A; Duran I; Odabaş AR; Kemal Işman F; Işbilen Başok B
    Ren Fail; 2016; 38(1):89-95. PubMed ID: 26539647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.
    Rattanasompattikul M; Molnar MZ; Zaritsky JJ; Hatamizadeh P; Jing J; Norris KC; Kovesdy CP; Kalantar-Zadeh K
    Nephrol Dial Transplant; 2013 Jul; 28(7):1936-45. PubMed ID: 23045431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
    El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
    Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.
    Panichi V; Rosati A; Paoletti S; Ferrandello P; Migliori M; Beati S; Bernabini G; Daini R; Casani A; Angelini D; Parrini M; Rossi A; Petrone I; Barsotti G; Donadio C; Donati G; Grazi G; Manca Rizza G; Garosi G; Sansoni E; Braccagni B; Sidoti A; Boracelli D; Biagioli M; Moriconi L; Finato V; Mannarino A; Grimaldi C; Pansa F; Imperiali P; Mura C; Bianchi S; Bigazzi R
    Blood Purif; 2011; 32(1):7-14. PubMed ID: 21242686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study.
    Panichi V; Rosati A; Bigazzi R; Paoletti S; Mantuano E; Beati S; Marchetti V; Bernabini G; Grazi G; Rizza GM; Migliori M; Giusti R; Lippi A; Casani A; Barsotti G; Tetta C;
    Nephrol Dial Transplant; 2011 Aug; 26(8):2641-8. PubMed ID: 21325348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.
    Marcelli D; Bayh I; Merello JI; Ponce P; Heaton A; Kircelli F; Chazot C; Di Benedetto A; Marelli C; Ladanyi E; Kroczak M; Stuard S; Grassmann A; Scatizzi L; Brand K; Canaud B
    Kidney Int; 2016 Jul; 90(1):192-202. PubMed ID: 27178833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
    Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
    Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients.
    Okazaki M; Komatsu M; Kawaguchi H; Tsuchiya K; Nitta K
    Blood Purif; 2014; 37(2):106-12. PubMed ID: 24603656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study.
    Fujii H; Hamano T; Tsuchiya K; Kuragano T; Joki N; Tsuruya K; Honda H; Uemura Y; Nitta K;
    Int J Cardiol; 2023 Mar; 375():110-118. PubMed ID: 36592827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between hyporesponsiveness to erythropoiesis-stimulating agents and risk of brain hemorrhage in patients undergoing hemodialysis: the Q-Cohort Study.
    Uchida Y; Nakano T; Kitamura H; Taniguchi M; Tsuruya K; Kitazono T
    Clin Exp Nephrol; 2023 Jan; 27(1):79-88. PubMed ID: 36100804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study.
    Fujikawa T; Ikeda Y; Fukuhara S; Akiba T; Akizawa T; Kurokawa K; Saito A
    Nephron Clin Pract; 2012; 122(1-2):24-32. PubMed ID: 23486237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation.
    Teatini U; Liebchen A; Nilsson LG; Beck W; Longhena GR
    Blood Purif; 2016; 41(1-3):80-6. PubMed ID: 26536083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency.
    Won HS; Kim HG; Yun YS; Jeon EK; Ko YH; Kim YS; Kim YO; Yoon SA
    Hemodial Int; 2012 Jan; 16(1):31-7. PubMed ID: 22284696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
    Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
    Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial.
    Lim JH; Jeon Y; Yook JM; Choi SY; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Cho JH
    Sci Rep; 2020 Sep; 10(1):16062. PubMed ID: 32994531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.